A Case of COVID-19 and <i>Pneumocystis jirovecii</i> Coinfection

Menon, Aravind; Berg, David D.; Brea, Elliott J.; Deutsch, Aaron J.; Kidia, Khameer; Thurber, Emilia G.; Polsky, Sylvie B.; Yeh, Tiffany; Duskin, Jonathan; Holliday, Alison M.; Gay, Elizabeth; Fredenburgh, Laura E.

doi:10.1164/rccm.202003-0766le

Cited by 73 publications

(84 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings added the clinical suspicion of PjP and addressing additional laboratory testing for the confirmation of this coinfection [36]. But, it is also important to mention that similar situations have been reported in persons who are not living with HIV [35,37].…”

Section: Discussionsupporting

confidence: 53%

Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV—A Case Report from Argentina and Literature Review

Messina

Marín

Cáceres

et al. 2020

JoF

View full text Add to dashboard Cite

The disease caused by the new SARS-CoV-2, known as Coronavirus disease 2019 (COVID-19), was first identified in China in December 2019 and rapidly spread around the world. Coinfections with fungal pathogens in patients with COVID-19 add challenges to patient care. We conducted a literature review on fungal coinfections in patients with COVID-19. We describe a report of a patient with disseminated histoplasmosis who was likely infected with SARS-CoV-2 and experienced COVID-19 during hospital care in Buenos Aires, Argentina. This patient presented with advanced HIV disease, a well-known factor for disseminated histoplasmosis; on the other hand, we suspected that COVID-19 was acquired during hospitalization but there is not enough evidence to support this hypothesis. Clinical correlation and the use of specific Histoplasma and COVID-19 rapid diagnostics assays were key to the timely diagnosis of both infections, permitting appropriate treatment and patient care.

show abstract

Section: Discussionsupporting

confidence: 53%

Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV—A Case Report from Argentina and Literature Review

Messina

Marín

Cáceres

et al. 2020

JoF

View full text Add to dashboard Cite

show abstract

“…We read with great interest the letter “A Case of COVID-19 and Pneumocystis jirovecii Coinfection” by Menon and colleagues ( 1 ) that reports a cooccurrence of coronavirus disease (COVID-19) and pneumocystosis in an 83-year-old non–HIV-infected female. The authors hypothesize that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection led to a state of functional immune suppression related to lymphocytopenia (absolute lymphocyte count 1,090 cells/μl), predisposing the patient to Pneumocystis jirovecii infection.…”

mentioning

confidence: 99%

COVID-19–related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis

Blaize

Mayaux

Luyt

et al. 2020

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Table 1: characteristic of ICU patients for severe COVID-19 for whom a specific research for Pneumocystis jirovecii pneumonia has been conducted 1 All HIV infected patients received antiretroviral therapy at the time COVID-19 was diagnosed. Five patients had absolute CD4+ lymphocytes cells > 200/µL; one patient had 184 CD4+ lymphocytes cells/µL 2 Dexamethasone 20 mg/day or high dose prednisone (3-5 mg/kg/day)

show abstract

“…Adicionalmente, se manifiesta que las neumonías por COVID-19 y P. jirovecii, comparten características clínicas como infiltrados multifocales bilaterales e hipoxemia profunda. Por otro lado, la coinfección con P. jirovecii, puede no ser detectada en pacientes con infección grave por SARS-CoV-2 y la condición puede revestir mayor gravedad si estos presentan condición de inmunodeficiencia previa a la infección por SARS-CoV-2 (11,12,13,14).…”

Section: Introductionunclassified

Pneumocystis jirovecii y SARS-CoV-2; COVID-19

Forero

Lizarazú

Carreño

et al. 2020

nova

View full text Add to dashboard Cite

Pneumocystis jirovecii, es un agente fúngico oportunista causante de neumonía (pneumocistosis) que puede ser mortal en personas con condición de inmunocompromiso, incluyendo pacientes VIH con recuento de linfocitos T CD4+ < 200 céls/mm3 y en pacientes inmunocomprometidos por otras etiologías como trasplantes de órgano sólido y cáncer, entre otras. Muchas personas pueden ser portadoras sanas de este agente etiológico y actuar como reservorio y fuente de infección. Artículos relacionados con coinfección entre SARS-CoV-2 y los de carácter oportunistas como P. jirovecii y Aspergillus fumigatus empiezan a publicarse, donde se argumenta que esta infección viral tiene un alto riesgo de coinfección y se manifiesta la importancia de no excluir los patógenos respiratorios, como P. jirovecii, entre otros. La coinfección con P. jirovecii puede no ser detectada en pacientes con infección grave por SARS-CoV-2, dado que pueden compartir características clínicas comunes como infiltrados multifocales bilaterales e hipoxemia profunda entre otras. Por lo tanto, es necesario realizar pruebas diagnósticas adicionales para P. jirovecii en pacientes con infección por SARS-CoV-2, especialmente cuando se presenten otras características clínicas que pueden apoyar la coinfección, como hallazgos quísticos en la TC torácica y niveles elevados en sangre de 1,3-D-glucano, incluso en ausencia de factores de riesgo clásicos para P. jirovecii, para el diagnóstico de neumonía por Pneumocystis en pacientes con sospecha de infección por SARS-CoV-2.

show abstract

A Case of COVID-19 and Pneumocystis jirovecii Coinfection

Cited by 73 publications

References 12 publications

Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV—A Case Report from Argentina and Literature Review

Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV—A Case Report from Argentina and Literature Review

COVID-19–related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis

Pneumocystis jirovecii y SARS-CoV-2; COVID-19

Contact Info

Product

Resources

About